PKO Investment Management Joint Stock Co Buys 2,000 Shares of Illumina, Inc. (NASDAQ:ILMN)

PKO Investment Management Joint Stock Co grew its stake in Illumina, Inc. (NASDAQ:ILMN) by 133.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,500 shares of the life sciences company’s stock after purchasing an additional 2,000 shares during the period. PKO Investment Management Joint Stock Co’s holdings in Illumina were worth $278,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Fourth Dimension Wealth LLC bought a new stake in shares of Illumina in the fourth quarter valued at about $40,000. Bank Julius Baer & Co. Ltd Zurich acquired a new position in Illumina in the 4th quarter valued at approximately $45,000. Assetmark Inc. lifted its position in shares of Illumina by 954.8% in the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock worth $44,000 after acquiring an additional 296 shares during the period. Lee Danner & Bass Inc. acquired a new stake in shares of Illumina during the 4th quarter worth approximately $48,000. Finally, Rakuten Securities Inc. grew its holdings in shares of Illumina by 290.3% during the 1st quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company’s stock worth $29,000 after purchasing an additional 270 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Insider Buying and Selling

In related news, CFO Ankur Dhingra acquired 6,100 shares of the stock in a transaction on Monday, May 12th. The stock was purchased at an average price of $81.21 per share, for a total transaction of $495,381.00. Following the transaction, the chief financial officer now owns 24,906 shares of the company’s stock, valued at $2,022,616.26. The trade was a 32.44% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.17% of the stock is owned by corporate insiders.

Illumina Stock Down 0.9%

Shares of ILMN opened at $89.47 on Wednesday. The company has a market capitalization of $14.16 billion, a P/E ratio of -14.74, a PEG ratio of 1.77 and a beta of 1.33. Illumina, Inc. has a one year low of $68.70 and a one year high of $156.66. The business’s 50 day simple moving average is $79.75 and its 200-day simple moving average is $101.88. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.86 and a quick ratio of 1.48.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.96 by $0.01. The firm had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.03 billion. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. The business’s revenue for the quarter was down 1.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.98 EPS. As a group, sell-side analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently commented on ILMN. Barclays reduced their target price on Illumina from $100.00 to $77.00 and set an “underweight” rating for the company in a research report on Thursday, April 10th. Robert W. Baird reduced their price objective on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a report on Wednesday, March 5th. Piper Sandler decreased their target price on shares of Illumina from $190.00 to $185.00 and set an “overweight” rating on the stock in a research report on Thursday, May 15th. Canaccord Genuity Group upped their target price on shares of Illumina from $87.00 to $99.00 and gave the company a “hold” rating in a research note on Wednesday, June 11th. Finally, Guggenheim dropped their price target on shares of Illumina from $122.00 to $114.00 and set a “buy” rating for the company in a research report on Friday, May 9th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Illumina has a consensus rating of “Moderate Buy” and an average target price of $126.94.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.